01 Jan Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine

Posted at 00:00h in by

Authored by: Tang Michele W., Rhee Soo-Yon, Bertagnolio Silvia, Ford Nathan, Holmes Susan, Sigaloff Kim C., Hamers Raph L., Rinke de Wit Tobias F., Fleury Herve J., Kanki Phyllis J., Ruxrungtham Kiat, Hawkins Claudia A., Wallis Carole L., Stevens Wendy, van Zyl Gert U., Manosuthi Weerawat, Hosseinipour Mina C., Ngo-Giang-Huong Nicole, Belec Laurent, Peeters Martine, Aghokeng Avelin, Bunupuradah Torsak, Burda Sherri, Cane Patricia, Cappelli Giulia, Charpentier Charlotte, Dagnra Anoumou Y., Deshpande Alaka K., El-Katib Ziad, Eshleman Susan H., Fokam Joseph, Gody Jean-Chrysostome, Katzenstein David, Koyalta Donato D., Kumwenda Johnstone J., Lallemant Marc, Lynen Lutgarde, Marconi Vincent C., Margot Nicolas A., Moussa Sandrine, Ndung’u Thumbi, Nyambi Phillipe N., Orrell Catherine, Schapiro Jonathan M., Schuurman Rob, Sirivichayakul Sunee, Smith Davey, Zolfo Maria, Jordan Michael R., Shafer Robert W.
In: JOURNAL OF INFECTIOUS DISEASES 207(Suppl. 2), 2013, p.S70-S77
http://www.ncbi.nlm.nih.gov/pubmed/23687292